Literature DB >> 19837407

Impact of android overweight or obesity and insulin resistance on basal and postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities.

Nesrine Attia1, Natalie Fournier, Benoît Vedie, Michèle Cambillau, Philippe Beaune, Olivier Ziegler, Alain Grynberg, Jean-Louis Paul, Bruno Guerci.   

Abstract

Since android overweight/obesity and insulin resistance are independent risk factors for cardiovascular disease, we investigated their impact on basal and postprandial scavenger receptor BI (SR-BI) and ATP binding cassette transporter A1 (ABCA1)-mediated serum cholesterol efflux. Twelve android overweight to obese and 9 normal weight controls women underwent body composition analysis by dual energy X-ray absorptiometry, a euglycemic hyperinsulinemic clamp, and an oral fat load with blood sampling at initial time (T0), 4h (T4) and 10h (T10) after the fat load. Serum lipids and HDL-parameters, capacities of serum to promote cholesterol efflux from SR-BI expressing Fu5AH hepatoma cells or from ABCA1-expressing J774 macrophages and to abilities of serum to induce a net removal of cholesterol from macrophage foam cells were measured at T0, T4 and T10. Sera from overweight/obese exhibited moderately decreased SR-BI-mediated cholesterol efflux capacities, in accordance with reduced HDL concentrations, but importantly increased ABCA1-mediated cholesterol efflux and increased cholesterol extraction capacities over the postprandial period, partly related to higher prebeta-HDL concentrations. In multiple regression analyses, android obesity-related parameters and HDL-PL or prebeta-HDL levels remained the only independent correlates for SR-BI or ABCA1-dependent fractional cholesterol efflux while only prebeta-HDL levels remained correlated to cholesterol extraction capacities. Our results suggest that android overweight/obesity may not result in an impaired cholesterol efflux capacity. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837407     DOI: 10.1016/j.atherosclerosis.2009.09.025

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Changes in High-Density Lipoprotein Cholesterol Efflux Capacity After Bariatric Surgery Are Procedure Dependent.

Authors:  Sean P Heffron; Bing-Xue Lin; Manish Parikh; Bianca Scolaro; Steven J Adelman; Heidi L Collins; Jeffrey S Berger; Edward A Fisher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-21       Impact factor: 8.311

2.  High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.

Authors:  Bela F Asztalos; Katalin V Horvath; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

3.  The dynamin chemical inhibitor dynasore impairs cholesterol trafficking and sterol-sensitive genes transcription in human HeLa cells and macrophages.

Authors:  Emmanuelle Girard; Jean Louis Paul; Natalie Fournier; Philippe Beaune; Ludger Johannes; Christophe Lamaze; Benoît Védie
Journal:  PLoS One       Date:  2011-12-19       Impact factor: 3.240

4.  Effect of combined mulberry leaf and fruit extract on liver and skin cholesterol transporters in high fat diet-induced obese mice.

Authors:  Giuseppe Valacchi; Giuseppe Belmonte; Clelia Miracco; Hyeyoon Eo; Yunsook Lim
Journal:  Nutr Res Pract       Date:  2014-01-29       Impact factor: 1.926

5.  Theobromine Does Not Affect Fasting and Postprandial HDL Cholesterol Efflux Capacity, While It Decreases Fasting miR-92a Levels in Humans.

Authors:  Charlotte P J Talbot; Ronald P Mensink; Lotte Smolders; Virginie Bakeroot; Jogchum Plat
Journal:  Mol Nutr Food Res       Date:  2018-06-19       Impact factor: 5.914

6.  Exercise intervention alters HDL subclass distribution and function in obese women.

Authors:  Nicholas J Woudberg; Amy E Mendham; Arieh A Katz; Julia H Goedecke; Sandrine Lecour
Journal:  Lipids Health Dis       Date:  2018-10-10       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.